Tuomas R. Holmberg

Fundador en NovaDigm Therapeutics, Inc. .

Consumer Services

Health Technology

Perfil

Tuomas R.
Holmberg is the founder of NovaDigm Therapeutics, Inc. where he currently holds the title of Director & Chief Business Officer.
Mr. Holmberg is also the founder of Collector Crypt.
Mr. Holmberg's education history includes an MBA from the University of Southern California and an undergraduate degree from the California Institute of Technology.

Cargos activos de Tuomas R. Holmberg

Empresas	Cargo	Inicio
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Fundador	01/01/2005

Todos los cargos activos de Tuomas R. Holmberg

Antiguos cargos conocidos de Tuomas R. Holmberg.

Empresas	Cargo	Fin

Ver el detalle de la experiencia de Tuomas R. Holmberg.

Formación de Tuomas R. Holmberg.

University of Southern California	Masters Business Admin
California Institute of Technology	Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Tuomas R. Holmberg.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Health Technology